Meclofenamic Acid (Arquel)

Meclofenamic acid, marketed under the brand name Arquel, is a non-steroidal anti-inflammatory drug approved for use in horses to alleviate inflammation and pain associated with musculoskeletal conditions. This medication belongs to the fenamate class of NSAIDs, which are derived from anthranilic acid and possess a distinct chemical structure compared to other commonly used equine NSAIDs such as phenylbutazone or flunixin. Meclofenamic acid has established itself as a valuable therapeutic option particularly for horses suffering from laminitis and various forms of myositis where inflammation contributes significantly to clinical signs and discomfort.

The mechanism by which meclofenamic acid produces its therapeutic effects involves inhibition of cyclooxygenase enzymes responsible for converting arachidonic acid into prostaglandins and related inflammatory mediators. By reducing prostaglandin synthesis, the drug diminishes the inflammatory cascade that causes pain, swelling, and tissue damage at sites of injury or disease. Meclofenamic acid demonstrates good efficacy against both acute inflammatory conditions and chronic musculoskeletal problems, making it suitable for a range of clinical scenarios. The drug's effects typically become apparent within the first few days of treatment, with maximum benefit often observed after several days of consistent administration.

Arquel is supplied as oral granules designed for top-dressing on feed, providing a convenient administration route that most horses accept readily. The granular formulation mixes well with grain or pelleted feeds, allowing for straightforward once-daily dosing in the majority of clinical situations. This ease of administration makes meclofenamic acid particularly suitable for situations requiring treatment courses of several days to weeks, as owners can easily incorporate dosing into daily feeding routines without specialized equipment or techniques. The granules are typically well-tolerated from a palatability standpoint, though individual horses may occasionally show initial reluctance that usually resolves with continued exposure.

As with all non-steroidal anti-inflammatory drugs, meclofenamic acid carries the potential for adverse effects, particularly involving the gastrointestinal tract and kidneys. The drug should only be used under veterinary supervision following appropriate diagnosis of the underlying condition. Responsible use includes adhering to prescribed dosing regimens, monitoring the horse for adverse effects during treatment, and avoiding concurrent use with other NSAIDs or corticosteroids. Proper patient selection and monitoring help ensure that the benefits of therapy outweigh potential risks, allowing horses to receive effective pain relief and anti-inflammatory support while minimizing the likelihood of complications.

The primary indication for meclofenamic acid in horses is the treatment of acute and chronic laminitis, a painful and potentially debilitating condition affecting the laminar structures within the hoof. Laminitis involves inflammation and breakdown of the connections between the hoof wall and the coffin bone, causing severe pain that can render horses unable or unwilling to bear weight normally. Meclofenamic acid helps reduce the inflammatory component of laminitis, providing pain relief that allows affected horses to move more comfortably and reducing the mechanical forces that can worsen laminar damage. The drug is often incorporated into comprehensive laminitis management protocols that may also include dietary modification, mechanical support, and treatment of underlying causes.

Myositis, or inflammation of muscle tissue, represents another important indication for meclofenamic acid therapy. Horses may develop myositis from a variety of causes including overexertion, infectious agents, immune-mediated processes, and metabolic disturbances. Affected horses typically show muscle stiffness, pain on palpation, reluctance to move, and sometimes swelling of affected muscle groups. The anti-inflammatory properties of meclofenamic acid help reduce muscle inflammation and associated pain, supporting recovery and return to normal function. Horses with exertional myopathies may particularly benefit from appropriate NSAID therapy during acute episodes.

Soft tissue injuries encompassing tendons, ligaments, and surrounding structures respond favorably to meclofenamic acid therapy. Horses frequently sustain soft tissue injuries during athletic activities, accidents, or even routine turnout. The inflammatory response to tissue damage, while a necessary part of healing, can cause significant pain and potentially contribute to excessive scar tissue formation if uncontrolled. Judicious use of meclofenamic acid during the acute phase of soft tissue injuries helps manage inflammation and pain while the body initiates repair processes. Treatment duration and intensity should be tailored to injury severity under veterinary guidance.

General musculoskeletal pain from conditions such as arthritis, back pain, and joint inflammation may be effectively managed with meclofenamic acid. Older horses or those with significant athletic histories often develop degenerative joint changes that cause chronic discomfort and reduced performance. While meclofenamic acid does not reverse underlying joint pathology, it can significantly improve comfort and quality of life for affected horses. The drug may be used for periodic flare-ups of chronic conditions or as part of longer-term management strategies when appropriate monitoring is in place.

Veterinarians may also prescribe meclofenamic acid for post-surgical inflammation management, treatment of inflammatory conditions affecting the lower limbs, and supportive care for horses experiencing generalized inflammatory responses. The specific choice of meclofenamic acid over other available NSAIDs often depends on individual patient response, practitioner experience, cost considerations, and the specific characteristics of the condition being treated. Some horses that do not respond optimally to one NSAID may show improved response to another, making meclofenamic acid a valuable alternative option in the therapeutic arsenal.

Dosing of meclofenamic acid requires accurate determination of the horse's body weight to calculate the appropriate amount of medication. The standard dose for horses is 2.2 mg per kilogram of body weight, equivalent to 1 mg per pound, administered once daily. This translates to one gram of Arquel granules per one hundred pounds of body weight for products formulated at standard concentrations. A typical one thousand-pound horse would therefore receive ten grams of granules daily. Weight estimation using a properly calibrated weight tape provides acceptable accuracy for most horses, though scale weights are preferable when available, particularly for horses at the extremes of size ranges.

The recommended treatment duration with meclofenamic acid varies depending on the condition being treated and the individual horse's response. For acute inflammatory conditions, treatment courses of five to seven days are commonly prescribed, with reassessment at that point to determine if continued therapy is warranted. Chronic conditions such as ongoing laminitis or degenerative joint disease may require extended treatment periods, though continuous use beyond fourteen days should only occur with ongoing veterinary supervision and monitoring for adverse effects. The goal is to use the minimum effective dose for the shortest effective duration while achieving adequate pain control and anti-inflammatory effects.

Administration of Arquel granules is designed to be straightforward and owner-friendly. The measured dose of granules should be mixed thoroughly with a small amount of palatable feed to ensure complete consumption. Grain, pelleted feed, or moistened hay cubes work well as carrier feeds. Offering the medicated feed when the horse is hungry, such as at regular feeding times, helps ensure complete intake. Most horses consume the granules without difficulty once accustomed to the slight change in feed taste or texture. For reluctant feeders, mixing with a small amount of molasses or applesauce may improve acceptance without compromising drug absorption.

Timing of administration should remain consistent from day to day to maintain steady therapeutic drug levels. Once-daily dosing provides adequate coverage for most clinical situations, with the drug's duration of action spanning approximately twenty-four hours. Administering the dose at the same time each day, typically with morning or evening feeding, helps ensure compliance and optimal therapeutic effect. The drug may be given with or without food from an absorption standpoint, but mixing with feed improves palatability and ease of administration.

If a dose is missed, administer it as soon as remembered unless the next scheduled dose is approaching. In that case, skip the missed dose and resume the regular schedule with the next dose. Never double the dose to compensate for a missed administration, as this increases the risk of adverse effects without providing additional therapeutic benefit. For horses requiring critical pain management, missing doses may result in breakthrough pain, so establishing reliable dosing routines and having backup plans for administration helps maintain consistent therapy.

Treatment should continue for the full duration prescribed by the veterinarian even if the horse appears improved. Premature discontinuation may allow inflammation to rebound before adequate healing has occurred. Conversely, treatment should not be extended beyond the prescribed period without veterinary consultation, as prolonged NSAID use carries cumulative risks. If clinical signs persist or worsen despite appropriate treatment, veterinary reassessment is indicated to evaluate for complications, inadequate response, or the need for alternative therapeutic approaches.

Meclofenamic acid shares the general side effect profile common to non-steroidal anti-inflammatory drugs, with gastrointestinal effects representing the most frequently encountered adverse reactions. Most horses tolerate the medication well when administered at appropriate doses for recommended durations, experiencing no significant problems. However, understanding potential side effects allows for early recognition and appropriate response should they occur. Regular monitoring during treatment, including observation of appetite, attitude, and manure consistency, provides valuable early warning of developing problems.

Common gastrointestinal side effects include decreased appetite, mild digestive upset, and changes in fecal consistency. Some horses may show initial reluctance to eat or subtle reductions in feed consumption during the first days of treatment. Soft stools or mild diarrhea occasionally occur, typically resolving without specific intervention. These mild effects result from the drug's inhibition of protective prostaglandins in the gastrointestinal tract and usually remain manageable with continued treatment at appropriate doses. Providing adequate forage and ensuring good hydration may help minimize these effects.

More significant gastrointestinal complications include gastric ulceration and colonic inflammation, which can develop particularly with extended treatment, higher than recommended doses, or in predisposed individuals. Signs of serious gastrointestinal toxicity include persistent inappetence, weight loss, signs of abdominal discomfort or colic, grinding of teeth indicating gastric pain, and dark or tarry feces suggesting gastrointestinal bleeding. Right dorsal colitis, though more commonly associated with phenylbutazone, can occur with any NSAID and manifests as chronic diarrhea, protein loss, and progressive debilitation. Any horse showing these warning signs requires immediate veterinary evaluation and treatment discontinuation.

Renal effects represent another category of potential adverse reactions, as prostaglandins play important roles in maintaining kidney blood flow, particularly during periods of physiological stress. Horses that are dehydrated, in shock, or have pre-existing kidney disease are most vulnerable to NSAID-induced renal injury. Signs of kidney involvement may include decreased urination, development of edema in dependent areas, and general deterioration. Ensuring adequate hydration throughout treatment provides important protection against renal complications. Blood work to assess kidney function should be considered for horses receiving extended treatment courses.

Additional reported side effects include rare hypersensitivity reactions, potential effects on blood clotting through platelet function inhibition, and occasional hepatic effects. Allergic reactions may manifest as hives, facial swelling, or difficulty breathing and constitute emergencies requiring immediate veterinary attention. Abnormal bleeding from wounds or unusual bruising may indicate platelet dysfunction. Any unexpected clinical signs developing during treatment warrant veterinary consultation. Individual horses may show idiosyncratic responses not typical of the general population, reinforcing the importance of monitoring during therapy.

Meclofenamic acid should not be administered to horses with known hypersensitivity to the drug or to other members of the fenamate NSAID class. Horses that have previously experienced allergic reactions to meclofenamic acid, mefenamic acid, or related compounds should receive alternative medications. Cross-reactivity between different NSAID chemical classes can occur in some individuals, so horses with histories of severe reactions to any NSAID warrant careful evaluation before meclofenamic acid therapy. Complete medication history should be provided to the prescribing veterinarian to enable safe treatment selection.

Pre-existing gastrointestinal disease, particularly active ulceration of the stomach or colon, represents a significant contraindication to meclofenamic acid use. The drug's mechanism of action reduces protective prostaglandins in the gastrointestinal tract, which can dramatically worsen existing ulcerative lesions and potentially precipitate perforation with life-threatening consequences. Horses with histories of NSAID-induced gastrointestinal toxicity, including previous right dorsal colitis, gastric ulceration requiring treatment, or unexplained chronic diarrhea, should generally avoid meclofenamic acid. When anti-inflammatory therapy is essential in these patients, alternative approaches should be explored with veterinary guidance.

Kidney disease or renal insufficiency contraindicates meclofenamic acid use due to the drug's potential to further compromise renal function through prostaglandin inhibition. Horses with known kidney problems, elevated kidney values on blood work, or clinical signs suggesting renal dysfunction should not receive this medication without careful consideration of alternatives. Similarly, horses that are significantly dehydrated, experiencing hemorrhage, or in cardiovascular shock should not receive meclofenamic acid until their fluid and circulatory status has been stabilized. Administering NSAIDs to hypovolemic horses risks precipitating acute kidney injury.

Pregnant mares should generally avoid meclofenamic acid, particularly during late gestation, due to potential effects on fetal development and the normal processes of parturition. Prostaglandins play important roles in maintaining fetal circulation and initiating labor, and their inhibition can have adverse consequences. Lactating mares can receive meclofenamic acid when medically necessary, though nursing foals should be monitored for any adverse effects as the drug may pass into milk. Horses intended for competition must observe appropriate withdrawal times, as meclofenamic acid is a regulated substance under most equestrian governing body rules. Horses destined for human consumption in jurisdictions where this occurs face extended withdrawal requirements or prohibition of treatment.

The most critical drug interaction involving meclofenamic acid is concurrent administration with other non-steroidal anti-inflammatory drugs. Combining NSAIDs, commonly termed stacking, dramatically amplifies the risk of severe gastrointestinal ulceration, acute kidney injury, and other serious adverse effects. This prohibition applies to all NSAIDs used in equine practice including phenylbutazone, flunixin meglumine, firocoxib, ketoprofen, meloxicam, and aspirin. Never administer meclofenamic acid to a horse that has received another NSAID without first observing an appropriate washout period. A minimum of twenty-four to forty-eight hours between different NSAIDs is recommended, with longer intervals preferable for drugs with extended half-lives.

Corticosteroid drugs interact with meclofenamic acid by compounding effects on the gastrointestinal tract, as both drug classes affect prostaglandin-mediated mucosal protection. Concurrent use of corticosteroids and NSAIDs significantly increases ulceration risk beyond that seen with either drug class alone. When treatment with both drug types is medically necessary, gastric protectants such as omeprazole should be administered, and treatment duration should be minimized. Transitioning between corticosteroid and NSAID therapy requires a washout period to reduce cumulative gastrointestinal toxicity risk. Careful coordination between veterinary professionals ensures safe management when both drug classes are indicated.

Meclofenamic acid may interact with other highly protein-bound drugs through competition for plasma protein binding sites. Such interactions can alter the free fraction of both drugs, potentially affecting their activity and elimination. Medications of potential concern include certain antibiotics, particularly sulfonamides, and other highly bound therapeutic agents. Aminoglycoside antibiotics, which carry their own nephrotoxicity potential, may have additive effects with meclofenamic acid on kidney function. When treating horses on multiple medications, veterinary oversight ensures appropriate drug selection and monitoring for potential interactions.

Competition horses require attention to drug interactions that may affect withdrawal times or complicate regulatory compliance. Some drug combinations may alter metabolism, potentially extending detection windows beyond expected timeframes. Herbal supplements or nutraceuticals may contain undeclared compounds that interact with meclofenamic acid or create detection issues. Detailed medication records and consultation with both the treating veterinarian and regulatory body representatives help ensure compliance with competition rules. When multiple medications are necessary, conservative withdrawal time estimates should be applied to protect against inadvertent positive tests.

Monitoring requirements during meclofenamic acid therapy should be proportionate to treatment duration and patient risk factors. For short treatment courses in otherwise healthy horses, daily observation for appetite changes, attitude alterations, and fecal consistency provides adequate surveillance for most patients. Extended treatment beyond seven to fourteen days warrants consideration of blood work to assess kidney and liver function, along with evaluation for gastric ulcer development. Horses with pre-existing health conditions or advanced age may benefit from baseline laboratory assessment before initiating treatment and periodic monitoring throughout therapy.

Special patient populations require additional precautions when receiving meclofenamic acid. Foals and young horses have developing organ systems and may metabolize drugs differently than mature horses, warranting conservative dosing and vigilant monitoring. Geriatric horses commonly have diminished reserve in kidney and liver function, increasing vulnerability to drug-induced injury even at standard doses. Shorter treatment courses and periodic assessment help protect these patients. Horses with pituitary pars intermedia dysfunction or equine metabolic syndrome face elevated laminitis risk, and while meclofenamic acid may help manage laminitis pain, masking discomfort without addressing underlying metabolic issues can be counterproductive.

Competition horse owners and trainers must carefully observe withdrawal time requirements for meclofenamic acid under applicable regulations. The Fédération Équestre Internationale, United States Equestrian Federation, and state racing commissions all regulate NSAID use in competition horses. Detection times vary based on dose, duration of treatment, and individual metabolism. Withdrawal time recommendations indicate when drug levels are expected to fall below detection thresholds but cannot guarantee negative tests, as individual variation exists. Competition horses should receive extended withdrawal periods when possible, and precise medication administration records should be maintained.

Safe handling of meclofenamic acid granules includes basic precautions to prevent human exposure. While the granular formulation presents relatively low exposure risk during normal handling, washing hands after administration is advisable. Avoid inhaling dust from the granules, and do not allow the medication to contact eyes or mucous membranes. Keep the medication secured away from children and clearly labeled to prevent accidental ingestion. Dispose of unused medication according to local regulations rather than discarding in household waste or flushing.

Long-term use considerations become increasingly important as treatment duration extends. Continuous NSAID therapy beyond two weeks should prompt reassessment of the underlying condition and exploration of alternative or adjunctive management strategies. Drug holidays, during which treatment is temporarily suspended, may help reduce cumulative toxicity while maintaining adequate long-term control. Gastroprotective therapy with omeprazole should be considered for horses requiring extended NSAID treatment. Chronic pain conditions often benefit from multimodal approaches that reduce reliance on any single drug class, incorporating physical therapy, joint-targeted treatments, and appropriate exercise modification alongside pharmacological management.

Meclofenamic acid granules should be stored at controlled room temperature, typically between fifteen and thirty degrees Celsius or fifty-nine to eighty-six degrees Fahrenheit, to maintain stability and efficacy. The product should be kept in a dry environment, as moisture exposure can cause granules to clump or degrade. Original packaging provides the best protection against environmental factors and should be resealed securely after each use. Store away from direct sunlight and heat sources, which can accelerate degradation of the active ingredient. Barn storage is acceptable if temperature and humidity conditions remain within acceptable ranges, though climate-controlled locations offer better long-term stability.

Proper handling practices protect both the medication and the individuals administering it. Measure doses carefully using appropriate equipment such as a kitchen scale or calibrated scoop to ensure accurate dosing. Avoid creating dust when handling granules, and wash hands thoroughly after measuring and administering the medication. While meclofenamic acid poses relatively low risk from incidental skin contact, preventing unnecessary exposure represents good practice. Keep the medication container clearly labeled and stored separately from human medications, foods, and supplements to prevent accidental confusion or consumption.

Attention to expiration dates ensures medication safety and efficacy. Products should be used before the manufacturer's expiration date printed on packaging, as potency and stability cannot be guaranteed beyond this point. Expired meclofenamic acid should be disposed of appropriately rather than administered to horses. Inspect granules before use for any signs of discoloration, unusual odor, excessive clumping, or other changes that may indicate degradation. Proper disposal of expired or unwanted medication follows local regulations, which may include veterinary take-back programs, pharmacy disposal services, or approved medication disposal facilities. Avoid disposing of medications in household trash accessible to animals or children, and never flush or wash medications down drains where they can enter water systems.

Draft breeds including Clydesdales, Shires, Percherons, and Belgians require careful attention to dosing accuracy due to their substantially greater body mass compared to light horse breeds. Accurate weight determination becomes particularly important, as the potential for both underdosing and overdosing increases when working with horses weighing over seven hundred kilograms. Standard weight tapes often underestimate draft horse weights, and scale weights should be obtained when possible. Some veterinarians advocate slightly conservative initial dosing in draft breeds with adjustment based on clinical response. Draft horses may have different metabolic characteristics than lighter breeds, though research specifically examining meclofenamic acid pharmacokinetics in draft breeds is limited.

Light horse breeds and warmbloods typically follow standard dosing recommendations without significant modification. Performance horses in these categories often maintain lean body compositions, making weight-based dosing calculations generally straightforward. Competition horses require careful attention to withdrawal time requirements under applicable regulatory frameworks. Some breed registries or discipline organizations maintain specific medication policies that may differ from general competition rules. Thoroughbreds and similar hot-blooded breeds may occasionally show heightened sensitivity to medications, warranting observation during initial treatment.

Ponies and miniature horses demand exceptional precision in dosing due to their small size, where even minor measurement errors can produce clinically significant under or overdosing. These smaller equines frequently suffer from metabolic conditions including equine metabolic syndrome and insulin dysregulation, predisposing them to laminitis. While meclofenamic acid may help manage laminitis pain, addressing the underlying metabolic dysfunction remains essential for long-term management. The medication should not substitute for appropriate dietary restriction, weight management, and treatment of metabolic disorders. Owners of ponies and miniatures should work closely with their veterinarians to ensure appropriate NSAID use within comprehensive management plans.

Breed-specific genetic conditions may influence meclofenamic acid therapy in various ways. Quarter Horses and related breeds carrying genes for polysaccharide storage myopathy may experience muscle pain benefiting from NSAID therapy, though metabolic management remains paramount. Horses with hyperkalemic periodic paralysis require attention to overall medication and stress management. Arabian horses with genetic conditions affecting organ function may require adjusted approaches. Friesians have elevated rates of megaesophagus, which could theoretically complicate oral medication delivery, though the granular formulation mixed with feed is generally well-tolerated. Individual assessment should always guide treatment decisions rather than breed generalizations alone.

Within the NSAID category, several alternative medications exist for equine musculoskeletal and inflammatory conditions. Phenylbutazone remains the most widely prescribed oral NSAID in equine practice, offering excellent efficacy against bone and joint pain at relatively low cost. Flunixin meglumine provides superior visceral analgesia making it the preferred choice for colic-related pain. Firocoxib, a COX-2 preferential inhibitor, may offer improved gastrointestinal safety for horses requiring extended anti-inflammatory therapy. Ketoprofen provides potent anti-inflammatory effects in injectable formulation. The selection among these agents depends on the specific clinical situation, individual patient factors, cost considerations, and veterinary preference based on experience.

When NSAIDs are contraindicated or provide insufficient effect alone, alternative analgesic approaches expand therapeutic options. Opioid medications including butorphanol and morphine provide analgesia through different mechanisms than NSAIDs and may be used adjunctively or alternatively. Acetaminophen has gained acceptance in equine practice as an analgesic that does not inhibit prostaglandins, avoiding the gastrointestinal and renal concerns associated with NSAIDs. Alpha-2 agonists such as detomidine and xylazine provide sedation with analgesia useful for acute pain situations. Gabapentin and other neuromodulators may help manage chronic or neuropathic pain. These alternatives are not direct substitutes for meclofenamic acid but rather expand the multimodal pain management toolkit.

Complementary and supportive therapies work alongside NSAID treatment to improve outcomes and potentially reduce drug requirements. Gastroprotective medications including omeprazole and sucralfate help prevent gastric ulceration during NSAID therapy. Joint supplements containing glucosamine, chondroitin, and hyaluronic acid support joint health in horses with degenerative conditions. Physical therapy modalities including therapeutic ultrasound, cold therapy, and controlled exercise programs complement pharmacological management. Intra-articular treatments with corticosteroids, hyaluronic acid, or regenerative medicine approaches provide targeted relief for specific joints. Any treatment modifications, including addition of complementary therapies or substitution of alternative medications, should occur under veterinary guidance to ensure safety and appropriate monitoring.